Stockscreener 앱 받기
12.15
3.67%
0.43
시간 외 거래:
12.25
0.10
+0.82%
전일 마감가:
$11.72
열려 있는:
$11.78
하루 거래량:
18,409
Relative Volume:
0.14
시가총액:
$233.42M
수익:
$54,000
순이익/손실:
$-210.26M
주가수익비율:
-15.38
EPS:
-0.79
순현금흐름:
$-159.01M
1주 성능:
+9.66%
1개월 성능:
+6.30%
6개월 성능:
-13.21%
1년 성능:
-52.54%
1일 변동 폭
$11.51
$12.26
1주일 범위
$10.76
$12.26
52주 변동 폭
$7.65
$32.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
12.15 | 225.16M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Can Lyell Immunopharma Inc. expand its profit marginsMarket Sentiment Report & Weekly Chart Analysis and Guides - خودرو بانک
Can Lyell Immunopharma Inc. reach all time highs this yearJuly 2025 Highlights & Daily Risk Controlled Trade Plans - خودرو بانک
Does Lyell Immunopharma Inc. stock reflect fundamentalsJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - خودرو بانک
Is Lyell Immunopharma Inc. in a bullish channelEarnings Growth Summary & Weekly High Conviction Trade Ideas - خودرو بانک
Using RSI to spot recovery in Lyell Immunopharma Inc.2025 AllTime Highs & Safe Entry Point Alerts - Newser
Is Lyell Immunopharma Inc. stock a good pick for beginners2025 Stock Rankings & Weekly High Conviction Ideas - خودرو بانک
Detecting support and resistance levels for Lyell Immunopharma Inc.Inflation Watch & Technical Pattern Alert System - Newser
Using Bollinger Bands to evaluate Lyell Immunopharma Inc.Weekly Trade Report & AI Forecasted Entry and Exit Points - Newser
Will Lyell Immunopharma Inc. stock go up soonJuly 2025 Selloffs & Real-Time Volume Analysis - Newser
Published on: 2025-09-05 00:39:52 - Newser
Published on: 2025-09-04 21:50:03 - Newser
What machine learning models say about Lyell Immunopharma Inc.Trade Analysis Summary & Technical Confirmation Trade Alerts - Newser
What the charts say about Lyell Immunopharma Inc. todayPortfolio Return Report & Verified High Yield Trade Plans - Newser
Using data models to predict Lyell Immunopharma Inc. stock movementLayoff News & Verified Short-Term Plans - Newser
Intraday pattern recognizer results for Lyell Immunopharma Inc.Market Trend Summary & Daily Technical Forecast Reports - Newser
What is the Moat Score of Lyell Immunopharma Inc.2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - خودرو بانک
Will Lyell Immunopharma Inc. benefit from green energy policies2025 Support & Resistance & Weekly Watchlist for Hot Stocks - خودرو بانک
Applying big data sentiment scoring on Lyell Immunopharma Inc.July 2025 Technicals & AI Driven Price Forecasts - Newser
The Oncology Institute shares rise 1.23% intraday after Lyell Immunopharma initiates Phase 3 CAR T-cell therapy trial. - AInvest
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-To-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Initiates Phase 3 Trial Comparing Rondecabtagene Autoleucel to Approved CD19 CAR T-Cell Therapies for Aggressive Large B-Cell Lymphoma. - AInvest
Lyell Immunopharma Announces the Initiation of a Phase 3 - GlobeNewswire
First-Ever Head-to-Head CAR T Trial: Lyell's Dual-Target Therapy Takes On Standard Treatments in Lymphoma - Stock Titan
Price action breakdown for Lyell Immunopharma Inc.Bond Market & Real-Time Stock Price Movement Reports - Newser
Order flow analysis tools used on Lyell Immunopharma Inc.Market Risk Analysis & Consistent Return Strategy Ideas - Newser
Sector ETF performance correlation with Lyell Immunopharma Inc.Forecast Cut & Precise Buy Zone Identification - Newser
Lyell Immunopharma’s Strategic Momentum in CAR T-Cell Innovation and Commercial Readiness - AInvest
Can Traders Expect Breakout From Lyell Immunopharma Inc. This Week getLinesFromResByArray error: size == 0 - 강소기업뉴스
Lyell Immunopharma to Present at Investor Conferences - AInvest
Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewswire
Clinical-Stage CAR T-Cell Therapy Developer Lyell Immunopharma Announces Key September Investor Presentations - Stock Titan
Can Lyell Immunopharma Inc. grow without dilutionInsider Selling & Low Risk Growth Stock Ideas - خودرو بانک
Is Lyell Immunopharma Inc. a good stock for dollar cost averagingJuly 2025 Opening Moves & Target Return Focused Stock Picks - خودرو بانک
What candlestick patterns are forming on Lyell Immunopharma Inc.Weekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Multi factor analysis applied to Lyell Immunopharma Inc.2025 Trade Ideas & Scalable Portfolio Growth Ideas - Newser
RSI and MACD Indicate Shift in Lyell Immunopharma Inc. Sentiment2025 Big Picture & Weekly Hot Stock Watchlists - beatles.ru
Detecting price anomalies in Lyell Immunopharma Inc. with AIEarnings Overview Summary & AI Powered Market Entry Ideas - Newser
What technical models suggest about Lyell Immunopharma Inc.’s comebackCEO Change & Short-Term High Return Ideas - Newser
Identifying reversal signals in Lyell Immunopharma Inc.July 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - Newser
Visual trend scoring systems applied to Lyell Immunopharma Inc.Stock Surge & Free Safe Entry Trade Signal Reports - Newser
What momentum shifts mean for Lyell Immunopharma Inc.Market Risk Summary & Entry Point Confirmation Alerts - Newser
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lyell Immunopharma Inc 주식 (LYEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hill Stephen J. | Chief Operating Officer |
Aug 21 '25 |
Sale |
10.54 |
1,004 |
10,586 |
15,845 |
| Newton Charles W. | Chief Financial Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,306 |
| Lee Gary K. | Chief Scientific Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,504 |
| Seely Lynn | President and CEO |
Aug 12 '25 |
Sale |
10.34 |
406 |
4,197 |
34,828 |
| Seely Lynn | President and CEO |
Aug 11 '25 |
Sale |
10.53 |
391 |
4,116 |
35,234 |
| Hill Stephen J. | Chief Operating Officer |
Aug 12 '25 |
Sale |
10.34 |
94 |
972 |
8,849 |
| Hill Stephen J. | Chief Operating Officer |
Aug 11 '25 |
Sale |
10.53 |
91 |
958 |
8,943 |
| Lee Gary K. | Chief Scientific Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,957 |
| Lee Gary K. | Chief Scientific Officer |
Aug 11 '25 |
Sale |
10.53 |
131 |
1,379 |
9,093 |
| Newton Charles W. | Chief Financial Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,759 |
1.40%
자본화:
|
볼륨(24시간):